Recursion Pharmaceuticals, Inc.
RXRX
$5.68
-$0.27-4.54%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -121.60% | -92.38% | -3.04% | -27.13% | -39.87% |
| Total Depreciation and Amortization | 162.04% | 71.47% | -5.01% | 61.79% | 97.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 214.38% | 96.49% | 57.55% | 20.09% | 43.04% |
| Change in Net Operating Assets | 83.95% | 153.66% | 159.75% | -1.41% | -49.36% |
| Cash from Operations | -28.99% | -55.82% | 18.78% | -21.87% | -39.53% |
| Capital Expenditure | 72.46% | 37.20% | -512.35% | 70.21% | -28.56% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 390,387.32% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 0.00% | -100.00% | -- | -- |
| Cash from Investing | -9.27% | 11,171.38% | -1,214.70% | -103.70% | -24.59% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -7,773.08% | -202.74% | -9,429.17% | -8.33% | -8.33% |
| Issuance of Common Stock | 205.78% | -84.34% | -65.14% | 6,804.96% | 615.47% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 191.62% | -86.81% | -69.38% | 6,848.03% | 623.05% |
| Foreign Exchange rate Adjustments | 2,306.85% | -2,900.00% | 450.43% | -165.19% | -10,850.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.48% | 3,863.80% | -139.19% | 369.41% | -24.16% |